Literature DB >> 26751412

Prognostic factors in patients with malignant pleural effusion: Is it possible to predict mortality in patients with good performance status?

Fernando Conrado Abrao1, Renata D'Alpino Peixoto2, Igor Renato Louro Bruno de Abreu1, Maria Cláudia Janini1, Geisa Garcia Viana1, Mariana Campello de Oliveira1, Riad Naim Younes1.   

Abstract

BACKGROUND AND OBJECTIVES: The aim of this study was to identify predictors of mortality only in patients with malignant pleural effusion (MPE) showing good performance status which required pleural palliative procedures.
METHODS: All patients with MPE submitted to pleural palliative procedure were enrolled in a prospective study between 2013 and 2014. Patients with Eastern cooperative oncology group (ECOG) score zero, one, and two were considered with good performance status. The possible prognostic factors were tested for significance using the log-rank test (Kaplan-Meier method) and those with significance on univariate analysis were entered into a multivariable Cox model.
RESULTS: A total of 64 patients were included in the analysis. Median follow-up time for surviving patients was 263 days. Median survival for the entire cohort was not reached yet. In the multivariate analysis, gastrointestinal primary site (P = 0.006), low albumin concentration in the pleural fluid (P = 0.017), and high serum NLR (P = 0.007) were associated with mortality.
CONCLUSION: In our cohort of ECOG 0-2 patients with MPE submitted to pleural palliative procedures, gastrointestinal malignancy compared to other sites, low pleural fluid albumin and high NLR were significantly associated with mortality. The identification of these prognostic factors may assist the choice of the optimal palliative technique. J. Surg. Oncol. 2016;113:570-574.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  malignant; palliative care; pleura; pleural effusion; survival

Mesh:

Year:  2016        PMID: 26751412     DOI: 10.1002/jso.24168

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  9 in total

1.  Does the LENT score risk-stratify patients with malignant pleural mesothelioma? An observational study.

Authors:  Bertrand Chollet; Julien Guinde; Sophie Laroumagne; Hervé Dutau; Philippe Astoul
Journal:  Thorac Cancer       Date:  2021-05-05       Impact factor: 3.500

2.  Breast and Lung Effusion Survival Score Models: Improving Survival Prediction in Patients With Malignant Pleural Effusion and Metastasis.

Authors:  Sofia Molina; Gabriela Martinez-Zayas; Paula V Sainz; Cheuk H Leung; Liang Li; Horiana B Grosu; Roberto Adachi; David E Ost
Journal:  Chest       Date:  2021-05-11       Impact factor: 10.262

3.  Prognostic Factors of 30-day Survival of Patients with Malignant Pleural Effusion.

Authors:  Zulkifli Amin; Stephen Diah Iskandar
Journal:  Indian J Palliat Care       Date:  2017 Jul-Sep

4.  Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion.

Authors:  Jeong Uk Lim; Chang Dong Yeo; Hye Seon Kang; Chan Kwon Park; Ju Sang Kim; Jin Woo Kim; Seung Joon Kim; Sang Haak Lee
Journal:  Sci Rep       Date:  2019-03-18       Impact factor: 4.379

5.  Nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy.

Authors:  Jin Wang; Bowen Yang; Zhi Li; Jinglei Qu; Jing Liu; Na Song; Ying Chen; Yu Cheng; Simeng Zhang; Zhongqing Wang; Xiujuan Qu; Yunpeng Liu
Journal:  Ann Transl Med       Date:  2020-03

6.  Clinical course of asymptomatic malignant pleural effusion in non-small cell lung cancer patients: A multicenter retrospective study.

Authors:  Jiyeon Roh; Hyo Yeong Ahn; Insu Kim; Ju Hyeong Son; Hee Yun Seol; Mi Hyun Kim; Min Ki Lee; Jung Seop Eom
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

7.  Total Protein-Chloride Ratio in Pleural Fluid Independently Predicts Overall Survival in Malignant Pleural Effusion at the First Diagnosis.

Authors:  Xin Qiao; Zhi-Rong Zhang; Xin-Yu Shi; Feng-Shuang Yi
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

Review 8.  Evaluation of the efficacy and safety of elemene in treating malignant pleural effusion caused by tumors: A PRISMA guided meta-analysis.

Authors:  Qing-Tao Wang; Ze-Lin Zhang; Hui Xiong; Dong-Sheng Zhou; Jun Li; Jian Liang; Ya-Fei Wang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

9.  Prognostic factors of recurrence of malignant pleural effusion: what is the role of neoplasia progression?

Authors:  Fernando Conrado Abrão; Igor Renato Louro B de Abreu; Mariana Campello de Oliveira; Geisa Garcia Viana; José Franklin Soares Pompa Filho; Riad Naim Younes; Elnara Marcia Negri
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.